Central Serous Chorioretinopathy and Micropulse Laser Treatment (LEVEO)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Central Serous Chorioretinopathy

Treatments: Other: Subthreshold Micropulse Laser Treatment

Study type: Observational

Funder types: Other

Identifiers

NCT06346405

10

Details and patient eligibility

About

To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
• Foveal serous retinal detachment for at least 6 months.
• Minimum age of 18 years old at the screening time
• Reading and comprehension skills of informed consent

Exclusion criteria

• Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
• No diffuse retinal epitheliopathy
• Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
• Not controlled glaucoma with eyedrops, or advanced glaucoma
• Myopia or hypermetropia greater than 6 diopters
• Opacities of dioptric media
• Low quality of optical coherence tomography (OCT) and OCT-Angiography scans
• Low quality images of Fluorescein angiography and indocyanine green angiography
• No written consensus signed.